ABOUT CARDIUM: Historical Background
October 2005 - Acquired a portfolio of biologic growth factors from the Schering AG Group for potential use in treating ischemic and other cardiovascular conditions, including Generx®, a product candidate being developed for patients with chronic myocardial ischemia
March 2006 - Acquired technologies and products of InnerCool Therapies, Inc., a medical technology company in the emerging field of therapeutic hypothermia or patient temperature modulation
August 2006 - Acquired Tissue Repair Company, a company focused on the development of therapeutics for the potential treatment of chronic wounds and other tissue injuries, including our Excellagen™ and Excellarate™ product candidates
July 2009 - Sold InnerCool Therapies to Royal Philips Electronics (NYSE: PHG)
December 2009 - Filed application for FDA 510(k) clearance for Excellagen™
June 2010 - Announced plans to initiate clinical study at three leading medical centers in Moscow for Cardium's Generx® product candidate
November 2010 - Launched the MedPodium™ modern lifestyle product line, a portfolio of premium, science-based, easy to use nutraceuticals, metabolics and aesthetics designed to promote health and well-being.